#Canada #Vancouver #Immunotherapy #BioVaxys #Share Consolidation

BioVaxys Technology Corp. Announces Share Consolidation

BioVaxys Technology Corp., a prominent player in biopharmaceuticals based in British Columbia, has made a significant announcement regarding its share structure. The company is set to undertake a consolidation of its common shares, which will transform 10 pre-consolidation shares into a single post-consolidation share. This strategic move, as detailed in their recent press release dated September 5, 2025, underscores the company's commitment to maintaining robust growth and optimizing their market positioning.

Overview of the Share Consolidation

The consolidation will take effect on September 11, 2025, when trading on the Canadian Securities Exchange (CSE) commences under the new arrangement. The ongoing shift will modify the total number of outstanding shares from approximately 293 million to about 29 million. This ratio of 10:1 is designed not only to streamline trading but also to potentially enhance the company's market appeal to investors looking for stability and growth.

Eligible shareholders who currently hold physical certificates will receive mailings that include a letter of transmittal with specifics on submitting their existing shares for the new consolidated shares. Notably, for shareholders without physical certificates, their shares will automatically convert to the new post-consolidation shares without any required action.

Adjustments for Existing Securities

Furthermore, the consolidation will affect other classes of securities convertible into common shares. The pricing and share ratios will be adjusted proportionally to reflect this consolidation, ensuring that the interests of all shareholders are preserved during this transition.

CEO Insights and Future Directions

James Passin, the CEO of BioVaxys, communicated that this move is essential not only for operational efficiency but also to enhance shareholder value in the long term. By consolidating their shares, BioVaxys is aligning itself more closely with institutional investors, who often prefer companies with a more favorable share structure for trading purposes. He expressed optimism that this consolidation strategy could attract more attention and credibility to their stock, paving the way for future investments and growth opportunities.

About BioVaxys Technology Corp.

BioVaxys is at the forefront of immunotherapy, utilizing innovative platforms like the DPX™ immune-educating technology for developing treatments for various cancers and immunological diseases. The company aims to significantly improve patient outcomes through cutting-edge therapies, and its clinical pipeline includes promising candidates like maveropepimut-S (MVP-S), which targets advanced cancers.

Their commitment to research and development has made BioVaxys a notable entity in the biotechnology sector, having established a diversified pipeline that addresses critical health needs, including innovative treatments for food allergies and infections. The anticipated outcomes from their unique immunotherapy approaches aim to redefine patient care in oncology, offering therapies that harness the power of the immune system.

Looking Ahead

As BioVaxys embarks on this consolidation journey, the company encourages shareholders and potential investors to stay tuned to their progress. The adjustments align with ongoing efforts to enhance clinical development and market strategies effectively, reflecting their determination to navigate the complexities of the rapidly evolving biopharmaceutical landscape. Shareholders can look forward to ongoing updates as the company continues to innovate and expand its impact in the field of healthcare.

In conclusion, the consolidation of shares by BioVaxys represents a significant strategic initiative. It clarifies their commitment to shareholder value and positions the company favorably for future advances in the biopharmaceutical sector. For more information about their initiatives and progress, interested parties are encouraged to visit BioVaxys' official website.

• ---